<i id='5E3C20386D'><strike id='5E3C20386D'><tt id='5E3C20386D'><pre id='5E3C20386D'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
ChatGPT in medicine: STAT answers readers' burning questions 
FDA gives detailed accounting of AI 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing 
Drug repurposing or repositioning? The language matters 
An Ebola outbreak presents a new mystery involving children 
Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen 
Solve the antibiotic resistance crisis with preventive drugs
Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen 
Judge schedules Friday hearing on proposed protective order in Jan. 6 case 
Heart attack and stroke risk calculators need revising
Solve the antibiotic resistance crisis with preventive drugs 
Affirmative action in medical school literally saved lives
Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing
ChatGPT in medicine: STAT answers readers' burning questions 
